Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cystic Fibrosis · Multiple Sclerosis · RARE

Ultragenyx UK

Ultragenyx UK Limited

Ultragenyx UK clinical programs — 201 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Newcastle upon tyne, NE128RL, GB, NOVATO, CA HQ
2024 Founded
2 Employees
Public company Type
RARE · NYSE Ticker
Company details
Status
Public
HQ
Newcastle upon tyne, NE128RL, GB, NOVATO, CA
Founded
2024
Employees
2
Programs
201
Drugs
168
Patents
23
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Ultragenyx UK projects

201 ClinicalTrials.gov programs sponsored by Ultragenyx UK.

Ultragenyx UK has 201 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

201 programs

Clinical programs

Page 1 of 5

  1. ,4-diaminopyridine

    Ultragenyx UK Limited

    Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

    phase 3 small molecule completed

    1 trial

  2. 2015-1949

    Ultragenyx UK Limited

    Eosinophilic Gastrointestinal Disorders (EGIDs)

    phase 3 small molecule completed

    1 trial

  3. 5 mg prednisone

    Ultragenyx UK Limited

    Granulomatosis With Polyangiitis

    phase 3 small molecule active

    2 trials

  4. Aceneuramic Acid Extended-Release Tablets

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy

    phase 3 small molecule terminated

    1 trial

  5. Adjuvant Immunomodulatory (IM) Therapy

    Ultragenyx UK Limited

    Mucopolysaccharidosis IIIA

    phase 3 small molecule active

    1 trial

  6. Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day

    Ultragenyx UK Limited

    Sanfilippo Syndrome

    phase 3 small molecule active

    1 trial

  7. Analatro

    Ultragenyx UK Limited

    Latrodectism

    phase 3 small molecule completed

    1 trial

  8. Anti-thymocyte globulin

    Ultragenyx UK Limited

    Aplastic Anemia

    phase 3 small molecule completed

    1 trial

  9. Bisphosphonate

    Ultragenyx UK Limited

    Osteogenesis Imperfecta

    phase 3 small molecule active

    1 trial

  10. Burosumab

    Ultragenyx UK Limited

    Hypophosphatemia

    phase 3 mab completed

    1 trial

  11. DTX301

    Ultragenyx UK Limited

    OTC Deficiency

    phase 3 gene therapy active

    1 trial

  12. DTX401

    Ultragenyx UK Limited

    Glycogen Storage Disease Type IA

    phase 3 gene therapy completed

    1 trial

  13. Evinacumab

    Ultragenyx UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  14. GTX-102

    Ultragenyx UK Limited

    Angelman Syndrome

    phase 3 small molecule active

    4 trials

  15. Plasma exchange

    Ultragenyx UK Limited

    Acute Disseminated Encephalomyelitis

    phase 3 other active

    1 trial

  16. Rifampicin

    Ultragenyx UK Limited

    Multiple System Atrophy

    phase 3 small molecule terminated

    1 trial

  17. Sirolimus

    Ultragenyx UK Limited

    Lymphangioleiomyomatosis

    phase 3 small molecule completed

    1 trial

  18. Tiratricol

    Ultragenyx UK Limited

    Monocarboxylate Transporter 8 Deficiency

    phase 3 small molecule completed

    1 trial

  19. Triheptanoin

    Ultragenyx UK Limited

    Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

    phase 3 small molecule active

    1 trial

  20. UX003

    Ultragenyx UK Limited

    Sly Syndrome

    phase 3 small molecule completed

    2 trials

  21. UX003

    Ultragenyx UK Limited

    MPS 7

    phase 3 small molecule completed

    1 trial

  22. UX007

    Ultragenyx UK Limited

    Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

    phase 3 small molecule terminated

    2 trials

  23. aceneuramic acid extended-release (Ace-ER)

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy

    phase 3 small molecule completed

    1 trial

  24. acyclovir

    Ultragenyx UK Limited

    Herpes Simplex

    phase 3 small molecule completed

    2 trials

  25. betamethasone

    Ultragenyx UK Limited

    Respiratory Distress Syndrome

    phase 3 small molecule completed

    1 trial

  26. colchicine

    Ultragenyx UK Limited

    Liver Cirrhosis, Biliary

    phase 3 small molecule completed

    1 trial

  27. conjugated estrogens

    Ultragenyx UK Limited

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  28. copolymer 1

    Ultragenyx UK Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  29. dehydroepiandrosterone

    Ultragenyx UK Limited

    Addison's Disease

    phase 3 small molecule completed

    1 trial

  30. dehydroepiandrosterone

    Ultragenyx UK Limited

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    3 trials

  31. desipramine

    Ultragenyx UK Limited

    Pain

    phase 3 small molecule completed

    1 trial

  32. dexamethasone

    Ultragenyx UK Limited

    Bronchopulmonary Dysplasia

    phase 3 small molecule completed

    1 trial

  33. diazepam

    Ultragenyx UK Limited

    Status Epilepticus

    phase 3 small molecule completed

    1 trial

  34. dichlorphenamide

    Ultragenyx UK Limited

    Paralysis, Hyperkalemic Periodic

    phase 3 small molecule completed

    1 trial

  35. diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis

    Ultragenyx UK Limited

    Pertussis

    phase 3 mab completed

    1 trial

  36. ganciclovir

    Ultragenyx UK Limited

    Cytomegalovirus Infections

    phase 3 small molecule completed

    1 trial

  37. guanfacine

    Ultragenyx UK Limited

    Tourette Syndrome

    phase 3 small molecule completed

    1 trial

  38. iloprost

    Ultragenyx UK Limited

    Systemic Sclerosis

    phase 3 small molecule completed

    1 trial

  39. immune globulin

    Ultragenyx UK Limited

    Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

    phase 3 small molecule completed

    2 trials

  40. immune globulin

    Ultragenyx UK Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  41. interferon alfa

    Ultragenyx UK Limited

    Hepatitis C

    phase 3 small molecule completed

    1 trial

  42. methotrexate

    Ultragenyx UK Limited

    Liver Cirrhosis, Biliary

    phase 3 small molecule completed

    1 trial

  43. methylprednisolone

    Ultragenyx UK Limited

    Spinal Cord Injury

    phase 3 small molecule completed

    1 trial

  44. mexiletine

    Ultragenyx UK Limited

    Pain

    phase 3 small molecule completed

    1 trial

  45. phenytoin

    Ultragenyx UK Limited

    Post-Traumatic Seizure Disorder

    phase 3 small molecule completed

    1 trial

  46. potassium citrate

    Ultragenyx UK Limited

    Hypercalciuria

    phase 3 small molecule completed

    1 trial

  47. prednisone

    Ultragenyx UK Limited

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    1 trial

  48. setrusumab

    Ultragenyx UK Limited

    Osteogenesis Imperfecta

    phase 3 mab active

    1 trial

Frequently asked questions

How many clinical projects does Ultragenyx UK have?

201 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.